<DOC>
	<DOCNO>NCT00227500</DOCNO>
	<brief_summary>This study randomise , placebo-controlled study effect treatment HMG-CoA reductase inhibitor , pravastatin , HIV-infected , protease inhibitor treat patient high serum cholesterol . We hypothesise pravastatin result great reduction cholesterol placebo use conjunction appropriate dietary advice .</brief_summary>
	<brief_title>Pravastatin Hyperlipidaemia HIV .</brief_title>
	<detailed_description>High serum cholesterol concentration commonly see HIV-infected patient treat protease inhibitor medication part long-term antiretroviral therapy HIV . There concern elevation cholesterol may negatively impact long-term risk cardiovascular disease patient population . Pravastatin , HMG-CoA reductase inhibitor , commonly use treat hypercholesterolaemia general population . We aim examine effect 12 week therapy 40mg pravastatin daily conjunction dietary advice HIV-infected patient elevate serum cholesterol continue protease inhibitor therapy . After 4 week dietary advice , patient randomise receive either pravastatin placebo 12 week . Assessments include fast lipid glycaemic parameter , measure body composition HIV disease , surrogate marker cardiovascular disease . Although previous small study pravastatin field perform , none do randomise placebo control trial take account relevant measure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Provide write informed consent participate trial HIV1 seropositive Male/female &gt; 18 year age Currently receive HIV protease inhibitor therapy &gt; 12 week unlikely require change exist regimen 16 week study period Fasting cholesterol &gt; 6.5 mmol/L ( mean 2 sample collect &gt; 3 day apart ) Any condition may interfere ability comply study Gastrointestinal disorder may affect drug absorption Hypertension congestive cardiac failure Lactic acidemia ( serum lactate level &gt; 2.2 mmol/L ) Any serious medical condition may compromise patient â€™ safety , include pancreatitis hepatitis within past 6 month Active AIDS defining condition Concurrent therapy lipid lower agent , oral hypoglycaemics , anabolic steroid insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Hyperlipidaemia</keyword>
	<keyword>Lipid metabolism</keyword>
	<keyword>Glucose metabolism</keyword>
	<keyword>HMG CoA reductase inhibitor</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV</keyword>
</DOC>